Compare CABR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABR | INTS |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.7M |
| IPO Year | 2025 | 2021 |
| Metric | CABR | INTS |
|---|---|---|
| Price | $0.66 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.67 |
| AVG Volume (30 Days) | ★ 131.4K | 13.8K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,215.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.22 |
| 52 Week High | $1.84 | $8.06 |
| Indicator | CABR | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 28.84 |
| Support Level | N/A | $0.22 |
| Resistance Level | $1.41 | $4.17 |
| Average True Range (ATR) | 0.20 | 0.27 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 13.64 | 13.88 |
Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.